Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Natco Pharma Q4 Results: Stock falls 9% as revenue drops 40%, margin shrinks
Natco Pharma reported a sharp decline in fourth-quarter revenue and operating profit, while margins contracted significantly year-on-year. The company’s shares fell over 9% following the earnings announcement.
Market Trading Guide: Buy Ramco Systems, Natco Pharma and 2 more stocks on Wednesday for gains up to 14% - The Economic Times
Market Trading Guide: Buy Ramco Systems, Natco Pharma and 2 more stocks on Wednesday for gains up to 14%The Economic Times
Market Trading Guide: Buy Ramco Systems, Natco Pharma and 2 more stocks on Wednesday for gains up to 14%
Nifty extended gains for a fourth session, confirming a breakout and positive near-term trend above key moving averages. Analysts highlight resistance at 23,200 and volatility risks from Middle East tensions, while recommending four stocks showing bullish patterns, momentum strength, and upside potential in coming weeks.
Natco Pharma shares gain 4% as board to mull demerger next week
Demerger: Natco Pharma shares gained nearly 4 per cent in trade on Friday ahead of next week's board meeting to consider a demerger proposal
Natco Pharma gains after launching generic diabetes drug Semaglutide
Natco Pharma jumped 2.77% to Rs 963 after the company announced the launch of Semaglutide Injection (multi dose vials) in the India market under the brand name of SEMANAT and SEMAFULL.
NATCO Pharma launches Semaglutide Injection (multi dose vials) in India
NATCO Pharma announced the launch of Semaglutide Injection (multi dose vials) in India market tomorrow on Day 1 of patent expiry.
Natco launches Rs 1,290 semaglutide in India, undercuts diabetes drug prices
Natco Pharma has launched a new generic semaglutide injection in India. This marks a significant step in making advanced diabetes treatment more accessible. The drug is available at a much lower price compared to existing options. This move is expected to benefit a large number of diabetic patients across the country.
NATCO Pharma board to consider agrochemicals demerger on March 24
The company also said the trading window for dealing in its securities will remain closed between March 19-26, and will reopen on March 27, in line with insider trading regulations. Shares of the company ended ₹957.90 apiece, up 1.59% on Wednesday, March 18.
Sensex Today Trades Higher | Nifty Above 24,100 | Natco Pharma Up 4% - Equitymaster
Sensex Today Trades Higher | Nifty Above 24,100 | Natco Pharma Up 4%Equitymaster
Today's Market: Sensex Today Trades Higher | Nifty Above 24,100 | Natco Pharma Up 4% - Indian Stock Market News - Equitymaster
Today's Market: Sensex Today Trades Higher | Nifty Above 24,100 | Natco Pharma Up 4% - Indian Stock Market NewsEquitymaster
Stocks to buy for short term: From BDL to Mazagon Dock— Jigar Patel of Anand Rathi recommends these 3 shares
Stocks to buy for the short term: Jigar Patel from Anand Rathi recommends three stocks—BDL, Mazagon Dock, and Natco Pharma—as potential buys for the next one to two weeks, citing strong technical indicators, strategic entry points, potential target prices, and stop losses.
Natco Pharma shares gain 3% after launching drug in the US for multiple myeloma treatment
The capsules, a thalidomide analogue, are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of last therapy, Natco Pharma said.